Alpaslan Bayrakdar
Alpaslan Bayrakdar publishes mostly in Organic Chemistry, Molecular Biology and Electronic, Optical and Magnetic Materials, on topics such as Synthesis and biological activity, Nonlinear Optical Materials Research and Enzyme function and inhibition.
- World rank
- #2,114,454 of 7,710,434 ranked researchers
- Rank in Türkiye
- #10,426 of 117,622
- Works
- 44
- Citations
- 377
- Citations per work
- 8.6
What does Alpaslan Bayrakdar research?
Alpaslan Bayrakdar's work is mostly in Chemistry (29%), Biochemistry, Genetics and Molecular Biology (9%), Materials Science (7%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences1840.4%
- Chemistry1328.7%
- Materials Science37.0%
- Computer Science24.7%
- Everything else1738.6%
- Life Sciences614.0%
- Health Sciences37.0%
- Medicine37.0%
- 1Organic Chemistry29% of their works
- 2Molecular Biology9% of their works
- 3Electronic, Optical and Magnetic Materials7% of their works
- 4Pharmacology7% of their works
- 5Plant Science5% of their works
- 6Computational Theory and Mathematics5% of their works
Research topics
- Synthesis and biological activity
- Nonlinear Optical Materials Research
- Enzyme function and inhibition
- Computational Drug Discovery Methods
- Synthesis and Characterization of Heterocyclic Compounds
- Free Radicals and Antioxidants
- Metal complexes synthesis and properties
- Cholinesterase and Neurodegenerative Diseases
Which keywords describe Alpaslan Bayrakdar's research?
The keywords of their largest research topics: Anticancer Agents, Medicinal Chemistry, Heterocyclic Compounds, Tubulin Inhibitors, Drug Discovery, Molecular Docking, Computational Chemistry and Nonlinear Optical Materials.
- Phenolic Compounds
- Cholinesterase Inhibitors
- Acetylcholinesterase
- Synthesis
- Inhibitors
- Carbonic Anhydrases
- Nonlinear Optical Materials
- Molecular Docking
- Tubulin Inhibitors
- Medicinal Chemistry
- Anticancer Agents
- Heterocyclic Compounds
- Drug Discovery
- Computational Chemistry
- Drug Development
- Drug Target Identification
- Virtual Screening
- Triazines
- Antioxidant
- Cisplatin Resistance
- Platinum-Based Drugs
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Anticancer Agents243 topics
- Medicinal Chemistry202 topics
- Heterocyclic Compounds141 topic
- Tubulin Inhibitors141 topic
- Drug Discovery112 topics
- Molecular Docking112 topics
- Computational Chemistry91 topic
- Nonlinear Optical Materials91 topic
- Drug Development82 topics
- Carbonic Anhydrases61 topic
- Drug Target Identification61 topic
- Inhibitors61 topic
- Virtual Screening61 topic
- Synthesis51 topic
- Triazines51 topic
- Acetylcholinesterase41 topic
- Antioxidant41 topic
- Cholinesterase Inhibitors41 topic
- Cisplatin Resistance41 topic
- Phenolic Compounds41 topic
- Platinum-Based Drugs41 topic
Where does Alpaslan Bayrakdar work?
Alpaslan Bayrakdar's main affiliation in the publication record is Iğdır Üniversitesi, Türkiye.
How many publications and citations does Alpaslan Bayrakdar have?
OpenAlex counts 44 works and 377 citations for Alpaslan Bayrakdar, an h-index of 12, ranking #2,114,454 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Alpaslan Bayrakdar. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.